Diabetes is a worldwide epidemic, and associated neuropathy is its most costly and disabling complication. Given the rising prevalence of painful diabetic neuropathy, it is increasingly important that we understand the best ways to diagnose and treat this condition. Diagnostic tests in this field are evolving rapidly. These include the use of skin biopsies to measure small unmyelinated fibers, as well as even newer techniques that can measure both small unmyelinated fibers and large myelinated fibers in the same biopsy. The main treatments for painful diabetic neuropathy remain management of the underlying diabetes and drugs for the relief of pain. However, emerging evidence points to major differences between type 1 and type 2 diabetes, including the ability of glycemic control to prevent neuropathy. Enhanced glucose control is much more effective at preventing neuropathy in patients with type 1 diabetes than in those with type 2 disease. This dichotomy emphasizes the need to study the pathophysiologic differences between the two types of diabetes, because different treatments may be needed for each condition. The impact of the metabolic syndrome on neuropathy in patients with type 2 diabetes may account for the difference between the two types of diabetes and requires further study. Finally, neuropathic pain is under-recognized and undertreated despite an ever evolving list of effective drugs. Evidence exists to support several drugs, but the optimal sequence and combination of these drugs are still to be determined.
Introduction
Painful diabetic neuropathy is a common condition that will only increase as the diabetes epidemic grows. 2 All physicians need to be aware of this under-recognized condition and be able to diagnose and treat neuropathy using the tests and drugs that have the best levels of evidence. Diagnostic testing continues to evolve, and some of these newer techniques can visualize nerve pathology without the need for a sural nerve biopsy. Randomized controlled trials for neuropathic pain continue to add to the levels of evidence for and against older and newer drugs. Finally, understanding the difference between type 1 and type 2 diabetes, including the role of the metabolic syndrome, has the potential to lead to new therapies for painful diabetic neuropathy that treat the underlying cause of the nerve injury rather than the resulting pain.
Epidemiology
Both type 1 diabetes, caused by insulin deficiency, and type 2 diabetes, caused by insulin resistance, are metabolic diseases that result in hyperglycemia. 3 Diabetes affects 8.5% of people in Europe and 8.3% in the United States, with annual treatment costs of $106bn (£63.4bn; €77bn) in Europe and $174bn in the US. 4 5 The most common complication is diabetic sensorimotor polyneuropathy, which occurs in 10-54% of patients with type 1 diabetes, 6 7 while retinopathy occurs in 26.5% of patients and nephropathy in 32%. 8 Similar rates exist in type 2 disease. 9 10 Symptoms of diabetic sensorimotor polyneuropathy typically manifest earlier in the course of type 2 diabetes than in type 1 disease-8% of patients have neuropathy at the time of diagnosis of type 2 diabetes. 11 A third of patients with diabetic sensorimotor polyneuropathy develop painful diabetic neuropathy, and this condition is more prevalent in type 2 diabetes than in type 1 disease. 1 Painful diabetic neuropathy has a negative impact on physical and mental quality of life (QOL) compared with painless diabetic neuropathy. 12 In painful diabetic neuropathy, most commonly associated with the diabetic sensorimotor polyneuropathy subtype, patients may describe burning, electric, or stabbing pain. Allodynia (painful sensations to innocuous stimuli) and hyperalgesia (increased sensitivity to painful sensations) are other common manifestations of diabetic sensorimo-
SOURCES AND SELECTION CRITERIA
We searched PubMed and Medline for articles on diabetic neuropathy, published from September 2008 to September 2013.
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Classification
Diabetic sensorimotor polyneuropathy is characterized by symmetric numbness, paresthesias, or pain in the distal lower limbs (or a combination thereof). 13 Examination may disclose stocking and glove sensory loss, impaired vibration and proprioception in the toes, reduced or absent Achilles tendon reflexes, and weakness or atrophy of the intrinsic muscles of the foot, which can result in foot abnormalities such as pes cavus and hammertoes. [13] [14] [15] Signs and symptoms progress in a centripetal fashion and are not confined to a single nerve or dermatomal distribution.
In 2004, an American Academy of Neurology consensus panel reviewed the literature to develop a case definition of distal symmetric polyneuropathy, with many of the reviewed studies evaluating diabetic sensorimotor polyneuropathy. They proposed that diagnostic accuracy is greatest when multiple neuropathic symptoms (pain, paresthesias, or numbness) and multiple neuropathic examination findings (sensory abnormalities or diminished reflexes) are present and electrodiagnostic studies confirm neuropathy, although sensitivity and specificity were not provided. 15 They also stated that multiple symptoms and multiple signs alone provide modest diagnostic accuracy. The main drawback to these guidelines was a lack of acknowledgment of a small fiber predominant neuropathy, typically in patients with type 2 diabetes. Skin biopsy with epidermal nerve fiber density has since been acknowledged by the European Federation of Neurological Societies as a sensitive measure of both diabetic and non-diabetic small fiber neuropathy (sensitivity was not provided). 2 16 In 2009, the Toronto consensus panel was convened to update the definition of diabetic sensorimotor polyneuropa-thy. The panel proposed the following definition: "a symmetrical, length-dependent sensorimotor polyneuropathy attributable to metabolic and microvessel alterations as a result of chronic hyperglycemia exposure and cardiovascular risk covariates."
2 It further defined painful diabetic polyneuropathy as "pain arising as a direct consequence of abnormalities in the peripheral somatosensory system in people with diabetes . . . the symptoms are distal, symmetrical, often associated with nocturnal exacerbations, and commonly described as prickling, deep aching, sharp, like an electric shock, and burning."
2 It proposed that patients with possible neuropathy should be defined as those with neuropathic symptoms, neuropathic sensory examination findings, or abnormal reflexes and patients with probable neuropathy as those with two of these three features. Confirmed clinical neuropathy was considered for those with either neuropathic symptoms or examination findings, including abnormal reflexes with documented abnormalities on nerve conduction studies or skin biopsy.
Small fiber neuropathy is another phenotype of painful diabetic neuropathy. Small diameter myelinated and unmyelinated fibers are affected, resulting in pain such as that seen in "burning feet" syndrome. 17 The Toronto consensus panel defined "possible" small fiber neuropathy as symptoms or signs of small fiber involvement.
2 "Probable" small fiber neuropathy requires the addition of a normal sural nerve sensory response on nerve conduction studies. "Definite" small fiber neuropathy requires the same criteria for probable small fiber neuropathy as well as a confirmatory test such as skin biopsy or quantitative sensory testing. Of note, most patients with diabetes and small fiber neuropathy have concomitant large fiber involvement or develop abnormalities in large fibers, transitioning to typical diabetic sensorimotor polyneuropathy.
Other subtypes of painful diabetic neuropathy include 29 30 In the past, histologic evaluation of nerves was limited to whole nerve biopsy, typically of the sural nerve. This method is not commonly used as a diagnostic test because of the side effects of the procedure, including a pain syndrome in the lateral part of the foot. In addition, nerve biopsy is rarely used in research studies because it cannot be repeated in the same location, which limits its usefulness as an endpoint in longitudinal studies. Sural nerve biopsy is usually abnormal-showing decreased myelinated nerve fiber density, swelling of axons, and segmental demyelination-even when signs of diabetic sensorimotor polyneuropathy are minimal or absent. 31 32 Biopsy of hairy skin in the lower extremities, followed by immunostaining and quantification of unmyelinated C fibers in the epidermis (intraepidermal nerve fiber density) is also a sensitive and reliable way to identify patients with diabetic sensorimotor polyneuropathy. 33 34 This method has the advantage of quantifying unmyelinated C fibers and places greater emphasis on the involvement of small unmyelinated fibers in the condition. The measurement of intraepidermal nerve fiber density is particularly important in patients with small fiber neuropathy, whose large fiber nerves are not affected and who therefore have normal nerve conduction studies. Longitudinal studies suggest that in patients with type 2 diabetes or pre-diabetes, loss of C fibers occurs before abnormalities in large myelinated fibers. 35 36 The major drawback to biopsy of hairy skin is the relative paucity of myelinated fibers in this type of skin. Biopsy of glabrous skin, found on the palms of the hands and soles of the feet, overcomes this obstacle, allowing a more accurate measurement of distal myelinated fiber density. 37 38 This method also shows a significantly greater involvement of myelinated fibers in patients with type 1 diabetes than in those with type 2 disease with similar severity of neuropathy, suggesting a difference in mechanism and natural course of diabetic sensorimotor polyneuropathy between the two type of diabetes. 39 The diagnosis of diabetic sensorimotor polyneuropathy for research purposes typically uses one of the published neuropathy scores, including the Michigan diabetes neuropathy score, 40 total neuropathy score, 41 and the lower limb neuropathy impairment score. 42 Most neuropathy scores include reflexes, perception of vibrations, monofilament sensation, strength of toe flexion or extension, and pinprick sensation. Scores are heavily biased towards functions associated with large myelinated fibers. An exception is the Utah early neuropathy score, which gives greater point value to loss or reduction of pinprick sensation and considers allodynia, both of which are mediated by small myelinated and unmyelinated fibers. 43 Screening surveys for neuropathic symptoms, which use questionnaires of symptoms without utilizing examination findings, can also be used. One such example is the Michigan neuropathy screening instrument, which has a diabetic lumbosacral radiculoplexus neuropathy, mononeuropathy, treatment induced neuropathy, and mononeuritis multiplex (fig 1) . Diabetic lumbosacral radiculoplexus neuropathy presents with asymmetric pain and weakness in the proximal lower limb. 18 Weight loss and improved glucose control, such as after starting insulin, can be associated features. Cervical and thoracic subtypes are also described. 19 20 No treatment has been proved to be effective in diabetic lumbosacral radiculoplexus neuropathy or its cervical and thoracic subtypes. Carpal tunnel syndrome is the most common mononeuropathy seen in patients with diabetes. 21 Other mononeuropathies that cause pain and are common in patients with diabetes include ulnar mononeuropathies at the elbow and lateral femoral cutaneous neuropathies (meralgia paresthetica). Treatment induced neuropathy is characterized by the acute onset of pain and autonomic dysfunction in the setting of improved glucose control. 22 This condition can occur after insulin or oral hypoglycemic drugs are started and patients often improve with time, particularly those with type 1 diabetes. Diabetic mononeuritis multiplex results in a stepwise progressive dysfunction of specific nerves and leads to pain, sensory loss, and weakness. 23 Peroneal and ulnar nerves are particularly susceptible. Perivascular infiltrates can be seen on biopsy, supporting an immune mediated vasculopathy.
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Diagnostic studies
Diabetic sensorimotor polyneuropathy is considered in patients with diabetes who have numbness, paresthesias, or pain and in those who present with ulcerations, loss of balance, falls, or injury owing to loss of sensation. The condition may also be recognized in patients with diabetes through screening algorithms that use monofilament testing or other quantitative sensory testing. 24 For greater specificity, both in clinical practice and in research, the diagnosis of diabetic sensorimotor polyneuropathy often requires abnormalities in at least one diagnostic test. The most commonly performed diagnostic tests are nerve conduction studies, which are reliable when performed by an experienced technician. 25 Such studies survey only large myelinated fibers, and the earliest changes noted are slowing of the conduction velocity of the sural sensory or peroneal motor responses and prolonged F wave latencies. 26 These are followed by a decrease in amplitude of the sural and peroneal responses, as well as prolonged distal latency of the peroneal motor response.
These changes occur after years of hyperglycemia in type 1 diabetes, yet in type 2 diabetes they are often detected before diagnosis, when the patient is in a pre-diabetic state. 27 A recent study found that changes in nerve conduction velocity and amplitude do not occur as fast in patients treated with modern glycemic goals as in those observed in the Diabetes Complications and Control Trial and Rochester diabetes cohort studies. 28 This suggests a change in the natural course of diabetic sensorimotor polyneuropathy secondary to stricter glycemic control goals. Also, owing to the typically short observation period of therapeutic trials in diabetic sensorimotor polyneuropathy, new tests that can detect smaller changes in nerve conduction are needed.
Another common clinical and research diagnostic test is to measure the perception of pressure and light touch with to preventing the onset and delaying the progression of neuropathy. Multiple large clinical trials of patients with type 2 diabetes have shown that intensive glycemic therapy delays the onset of diabetic sensorimotor polyneuropathy to a small degree, although this effect was not significant in a meta-analysis. 59 60 This is in contrast to several studies conclusively showing a large, significant benefit of preventing neuropathy with aggressive glycemic control in type 1 diabetes. 60 The Diabetes Complications and Control Trial also demonstrated the concept of metabolic memory in type 1 diabetes. 58 Patients randomized to intensive treatment continued to have a lower incidence of diabetic sensorimotor polyneuropathy and other microvascular complications than patients on conventional treatment even years after this last group of patients was switched to intensive therapy at trial completion. 56 In fact, patients in the intensive treatment group had a 64% relative risk reduction (45% to 76%) in the incidence of neuropathy compared with the conventional group. 57 Because compressive mononeuropathies are common in patients with diabetes, multiple surgical releases have been advocated for the treatment of diabetic sensorimotor polyneuropathy. 58 However, data supporting such surgical interventions are limited to uncontrolled case report series. No placebo controlled studies of surgical treatment have been performed, so these interventions are not currently recommended. 61 However, several non-randomized studies suggest that carpal tunnel syndrome and ulnar entrapment at the elbow improve significantly with surgical release. 62 63 Symptoms Pain relieving drugs for painful diabetic neuropathy fall into three major categories: antiepileptics, antidepressants that affect norepinephrine (noradrenaline) reuptake, and nonspecific analgesics, including opioids (box).
Pregabalin, duloxetine, and tapentadol are the only drugs approved by the US Food and Drug Administration for neuropathic pain in painful diabetic neuropathy. Duloxetine is also licensed in the European Union. Tapentadol is unique in that it has two mechanisms of action: activation of µ-opioid receptors and inhibition of norepinephrine reuptake. 64 
Antiepileptic drugs
In addition to pregabalin, the only other antiepileptic drug with demonstrated efficacy in treatment of diabetic neuropathic pain is gabapentin, which has a similar mechanism of action to pregabalin (binds to calcium channels in the dorsal horn containing the α2δ subunit and decreases neurotransmitter release). 65 Gabapentin and pregabalin have similar efficacy, with a number needed to treat (NNT) of 3.9-4.2.
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Gabapentin is licensed for neuropathic pain in the UK but not in the US.
Most antiepileptic drugs have shown limited benefit in painful diabetic neuropathy. Topiramate was not shown to be efficacious in phase III studies of diabetic neuropathic pain, although phase II studies were promising. 67 68 Placebo controlled studies of oxcarbazepine, lamotrigine, and lacosamide show conflicting results and no placebo controlled studies of carbamazepine exist. This raises questions of the efficacy of these drugs in diabetic neuropathic pain, sensitivity of 40% and a specificity of 92%. 44 These surveys typically include questions on pain, loss of sensation, common manifestations of allodynia, and distal autonomic impairment.
Quantitative sensory testing is also used for diagnosis in clinical research studies. The most common sensory modalities tested are vibration or thermal perception. 45 These tests are not as useful as clinical tests because they are subjective, dependent on patient cooperation, and may show abnormalities in patients without neuropathy. 46 However, quantitative sensory testing is more sensitive than nerve conduction studies and is highly reliable in research study populations. Unlike nerve conduction studies, these methods test the functionality of unmyelinated C fibers and can also be used for thermal perception.
Other diagnostic methods used to quantify C fiber function in research studies include quantitative sudomotor axon reflex testing, quantitative direct and indirect axon reflex, and sudoscan, which quantify the sudomotor C fibers that innervate sweat glands. [47] [48] [49] Laser Doppler flare imaging is used to study vasomotor C fibers that innervate superficial small arteries, which are responsible for vasodilation. 50 This imaging modality is abnormal in patients with diabetes and pre-diabetic neuropathy.
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Important patient outcomes
The important patient oriented outcomes in painful diabetic neuropathy are pain reduction, side effects of drugs, and QOL. The first two outcomes have been covered in previous sections. The HRQOL, a health related QOL tool developed for peripheral neuropathy, showed that severity of symptoms was more closely associated with QOL than electrophysiologic measures or examination findings. 52 Clinical trials, with limited time for secondary QOL endpoints, typically favor QOL measures that are shorter, with forced choice (Likert)-type answers rather than more individualized QOL scores. Generic QOL tools, such as the Nottingham Health Profile (NHP) and the Sickness Impact Profile (SIP), have also been used to assess the effectiveness of treatments. 52 53 Moreover, several different QOL tools have been developed for clinical trials of painful diabetic neuropathy. These include the Norfolk QOL Questionnaire-Diabetic Neuropathy, 54 Nottingham Health Profile, 55 PN-QOL, 52 and Neuro-QOL. 56 These tools contain 28-97 items that evaluate pain, disruption of daily activities, autonomic symptoms, and sexual functioning, as well as neuropathy specific sensory and motor items.
Patients with painful diabetic neuropathy have significantly decreased QOL scores owing to several factors, including pain, impaired balance and mobility, and frequent falling. Pain in itself has a large effect on QOL, including quality of sleep, mood, energy, and mobility. 57 Among the complications of diabetes, painful diabetic neuropathy was second only to amputation in decreasing QOL. 58 Further studies are needed on whether treatment of painful diabetic neuropathy improves QOL scores in patients with diabetes.
Treatment Prevention
The treatment of diabetic sensorimotor polyneuropathy is mostly preventive and symptom oriented. Management of the underlying diabetes continues to be the main approach its potent antioxidant properties and ability to reduce glutathione concentrations. 77 The largest trials included in the review are the SYDNEY, ALADIN, and SYDNEY2 trials. All of these trials showed that this drug provided benefit in patients with painful diabetic neuropathy. 78 79 The NATHAN 1 trial suggested that use of α lipoic acid (600 mg daily) improved neuropathy scores, and possibly delayed progression. 80 However, pain was not a predefined endpoint in these studies and the effect on pain control was only moderate.
Topical treatments
Topical treatments have had limited success in the treatment of painful diabetic neuropathy, largely because of a lack of placebo controlled trials and side effects. Capsaicin cream is approved for topical relief of neuropathic pain but many patients cannot tolerate it because of the initial pain on application. 81 Lidocaine cream or patches can be used for focal areas of pain but are less effective for more diffuse pain. Many pharmacies can produce creams with gabapentin or amitriptyline, which often include ketamine for pain control. These creams are not typically covered by health insurance, have no placebo controlled studies of efficacy, and may be cost prohibitive for some patients. However, for patients with multiple medical problems, these topical treatments may be of some benefit because of reduced drug interactions. 82 
Non-pharmacologic treatments
Two non-randomized studies with a before and after design found that exercise improved pain in pre-diabetic neuropathy and diabetic sensorimotor polyneuropathy as well as improving nerve fiber density on skin biopsy. 83 84 However, because these studies were not all blinded the optimum exercise routine is yet to be determined. Other non-phar-despite their use in other neuropathic pain conditions. [69] [70] [71] Sodium valproate demonstrated efficacy in two trials with methodologic concerns, and its side effects and safety profile make it unlikely to be used by most clinicians. 72 
Antidepressants with effects on norepinephrine reuptake
These have consistently shown benefit in the treatment of painful diabetic neuropathy, with a NNT between 2.1 and 5.5 to achieve 50% reduction in pain. 66 Amitriptyline, nortriptyline, and other tricyclic antidepressants have the advantage of once daily dosing, and they are economical owing to generic availability. However, they can have serious side effects, including orthostasis, constipation, somnolence, and erectile dysfunction. The newer serotonin-norepinephrine reuptake inhibitors (SNRIs) venlafaxine and duloxetine are also efficacious in painful diabetic neuropathy. 73 74 Opioid based drugs These drugs have known efficacy in the treatment of painful diabetic neuropathy. Placebo controlled studies show that oxycodone, morphine sulfate, tramadol, and tapentadol significantly improve pain in painful diabetic neuropathy (box). 7 75 Important drawbacks to opioid treatment include tolerance, withdrawal symptoms on discontinuation, and risk of misuse. In addition, the need to monitor opioid drugs using electronic prescription databases and urine drug screens makes opioid prescriptions labor intensive for many clinicians.
α lipoic acid A systematic review of α lipoic acid in the treatment of diabetic neuropathic pain found that this drug may help relieve pain and improve neuropathy, 76 possibly through support their use. 6 7 94 The American Diabetes Association also recommends at least 150 minutes of exercise a week (weight bearing and non-weight bearing) for patients with diabetes, including those with painful diabetic neuropathy or diabetic sensorimotor polyneuropathy. Patients with coexistent diabetic autonomic neuropathy are advised to seek cardiac evaluation before starting an exercise program.
What to discuss with patients Important items to discuss with patients with painful diabetic neuropathy are treatment of the underlying diabetes and management of the accompanying pain. As discussed earlier, the only known effective disease modifying treatment of painful diabetic neuropathy is enhanced glucose control. 60 The importance of diet and exercise must be emphasized despite obstacles for weight loss, such as long term adherence. Drugs including oral hypoglycemics and insulin need to be considered if diet and exercise do not adequately control glucose levels. Potential side effects of these drugs, such as hypoglycemia, should be explained, with a goal to minimize their occurrence.
Before pain can be managed, physicians must identify those patients who are affected. Observational studies indicate that more than 12% of patients with painful diabetic neuropathy have not talked about their pain with their physician and almost 40% of them have not received treatment for their pain. 95 Physicians should therefore ask all patients with diabetes about pain.
Once the diagnosis of painful diabetic neuropathy has been established, it is essential to discuss which drugs have the best levels of evidence to support their use. SNRIs, tricyclic antidepressants, and antiepileptic drugs that block calcium channels should be considered with a focus on potential treatments of comorbidities, minimizing side effects, and cost to the patient. For example, SNRIs and tricyclic antidepressants can treat concomitant anxiety and depression, so may be favored in patients with these common conditions. Potential side effects are also important to consider. For example, drugs that block calcium channels are metabolized by the kidneys, so they must be used carefully in patients with chronic kidney disease.
Finally, the cost to patients must be considered. Because these drugs have similar evidence of efficacy, newer drugs can be cost prohibitive and may result in non-compliance with treatment.
Other important discussion points include the risk of falls, foot ulceration, and amputation of the lower extremities secondary to loss of protective sensation. Patients with diabetic sensorimotor polyneuropathy are two to three times more likely to fall than patients with diabetes without neuropathy. 96 These falls can lead to fractures and other injuries, especially in elderly people. Appropriate evaluation for ankle foot orthoses and other ambulatory assist devices, in additional to gait therapy, can help prevent falls. Similarly, painful diabetic neuropathy is a major risk factor for the development of foot ulcers and the need for amputation of the lower extremities. 97 Foot care and evaluation by a physician will help reduce the likelihood of these severe outcomes.
In addition, risk factors such as tobacco and alcohol are important. Multiple studies suggest that smoking is a significant risk factor for diabetic sensorimotor polyneumacologic treatments used in painful diabetic neuropathy include transcutaneous electrical nerve stimulation, electromagnetic stimulation, spinal cord stimulation, deep brain stimulation, low level laser treatment, and massage, all of which have failed to demonstrate efficacy. 7 85-87 No placebo controlled studies exist for acupuncture.
Summary of evidence on treatment
Evidence supports the use of antiepileptic drugs that block calcium channels, serotonin norepinephrine reuptake inhibitors, and tricyclic antidepressants as first line drugs for relief of neuropathic pain (fig 2) . 5 88-90 Opioids can be considered when multiple first line agents alone or in combination do not control pain. 7 However, little evidence exists to compare these strategies and to determine the precise algorithm for their use.
Current evidence on painful diabetic neuropathy is limited by the lack of standardized assessments of pain, side effects, and QOL. Furthermore, longer trials of pain management are needed because most current trials study patients for months only. Trials to evaluate how and when to stop neuropathic drugs are also needed. Finally, the cost effectiveness of these drugs in painful diabetic neuropathy is rarely studied but will become increasingly important as healthcare resources become more limited.
Guidelines and recommendations
American Diabetes Association guidelines recommend screening for diabetic sensorimotor polyneuropathy at diagnosis of type 2 diabetes and five years after the diagnosis of type 1 disease, and then annually. Specifically, they recommend screening with clinical bedside tests of pinprick sensation, vibration perception using a 128 Hz tuning fork, or monofilament pressure sensation with a 10 g monofilament at the distal plantar aspect of both great toes and metatarsal joints, and assessment of ankle reflexes. 91 The International Diabetes Federation (IDF) also recommends screening with a 128 Hz tuning fork, biothesiometer, non-traumatic pinprick, or monofilament. It also recommends looking for other causes of neuropathy, including alcoholism, vitamin B 12 deficiency, renal disease, inherited neuropathies, vasculitis, and chronic inflammatory demyelinating polyneuropathy. 92 The American Diabetes Association recommends that physicians perform a foot examination, including inspection of the feet for deformities, cuts, ulcerations, and wounds in addition to sensation. Assessment for distal pulses is also recommended, and the ankle brachial index should be measured if peripheral arterial disease needs to be evaluated. Furthermore, patients with diabetes are encouraged to examine their feet daily and wear supportive footwear. 91 Treatment guidelines for painful diabetic neuropathy focus mainly on drugs for pain relief. Most studies are based on reducing pain on the 11 point Likert or visual analog scales. A reduction in pain of at least 30% is the primary outcome measure for most studies. 93 Treatment guidelines published by the American Academy of Neurology, Toronto Expert Panel meeting, and European Federation of Neurological Societies suggest that pregabalin, gabapentin, venlafaxine, duloxetine, tricyclic antidepressants, and opioids as the drugs with the best evidence to and the role of modifiable risk factors as a means of controlling both diabetic sensorimotor polyneuropathy and painful diabetic neuropathy. These modifiable factors may include components of the metabolic syndrome such as obesity, insulin resistance, hypertension, hypertriglyceridemia, and dyslipidemia. 117 With this in mind, future studies should investigate the size of the impact of the metabolic syndrome on diabetic sensorimotor polyneuropathy, and which specific components are the main drivers of nerve injury. Better understanding of how the metabolic syndrome relates to diabetic sensorimotor polyneuropathy may provide the basis for effective treatments. 117 The recently published evidence based guideline for the treatment of painful diabetic neuropathy identified areas for future research into drugs for pain. 7 Firstly, it notes a paucity of class I studies to evaluate the effectiveness of the drugs. Moreover, standardized and formalized scales for pain, QOL, and physical function are needed when comparing drugs against placebo, head to head or in combination with other treatments. In addition, because diabetic sensorimotor polyneuropathy is a chronic disease, trials of longer duration are needed. Finally, a better understanding of the side effects and cost effectiveness of these drugs in treating painful diabetic neuropathy is needed, because chronic use is anticipated.
Conclusions
Diabetic sensorimotor polyneuropathy is encountered by all types of physician and often results in pain. As the diabetic epidemic continues to grow, the prevalence of diabetic sensorimotor polyneuropathy and painful diabetic neuropathy will increase. Diagnostic tests to confirm neuropathy continue to evolve, with nerve conduction studies and skin biopsies the current mainstays of diagnosing large and small fiber nerve dysfunction, respectively. The management of diabetes is the only disease modifying treatment for diabetic sensorimotor polyneuropathy. However, several clinical trials in the past two decades have shown that glucose control is not sufficient to prevent neuropathy in patients with diabetes, especially in those with type 2 disease. 60 These consistent results indicate the need for understanding the differences between the two types of diabetes and of developing new treatments beyond glucose control.
Painful diabetic neuropathy is under-recognized and undertreated, which indicates the opportunity for improved patient care. 95 A growing number of drugs have strong evidence to support their use, but many other drugs have not shown benefit in clinical trials. Current evidence supports the use of antiepileptic drugs that block calcium channels, SNRIs, and tricyclic antidepressants as first line drugs in the treatment of neuropathic pain. 6 7 However, further studies are needed to develop new drugs and to determine the order and combinations that can best limit neuropathic pain. Limitations of past studies need to be tackled by using standardized assessments of pain, side effects, and QOL; studying drugs for longer periods of time; and evaluating the cost effectiveness of different strategies.
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ropathy. 98 99 Concurrent use of alcohol also may increase the risk of diabetic sensorimotor polyneuropathy. 100 Counseling about smoking and alcohol cessation should also be included as a therapeutic intervention.
Other causes of neuropathy, such as vitamin B 12 deficiency, which can be associated with metformin use, should also be assessed. 101 Furthermore, patients with diabetic sensorimotor polyneuropathy are at high risk of depression, with an odds ratio of 1.7 (1.1 to 2.77). 102 Patients with major depression have a high risk of developing foot ulceration, which is independent of glycemic control. 103 104 Physicians should therefore ask patients about depression and treat as necessary.
Challenging assumptions in diabetic neuropathy
For years, it has been assumed that hyperglycemia is the key driver of nerve injury in diabetic sensorimotor polyneuropathy. However, emerging data have shown that patients with type 1 and type 2 diabetes respond differently to enhanced glucose control. 60 More intensive treatment of hyperglycemia in patients with type 1 diabetes leads to a substantially lower incidence of neuropathy. 57 105 In contrast, enhanced glucose control has a minimal effect on the prevention of neuropathy in patients with type 2 diabetes. [106] [107] [108] [109] These results highlight the fact that type 1 and type 2 diabetes are different diseases that probably have different mechanisms of nerve injury.
In type 1 diabetes, the large effect of glucose control suggests that hyperglycemia is the primary driver of nerve injury, whereas in type 2 disease, the lack of effect implies that factors other than hyperglycemia are important. The metabolic syndrome possibly contributes to nerve injury given that the cardiovascular risk factors that comprise the syndrome often cluster together with diabetes. Two independent research teams have shown an association between the metabolic syndrome and neuropathy using cross sectional designs. [110] [111] [112] Other investigators have shown associations between individual components of the metabolic syndrome-including obesity, hypertension, low concentration of high density lipoprotein, and hypertriglyceridemia-and neuropathy. 12 98 Unresolved questions and emerging treatments The underlying mechanisms involved in diabetic sensorimotor polyneuropathy need to be identified so that disease modifying treatments can be developed. This includes, but is not limited to, understanding the roles of oxidative stress, inflammation, and altered gene expression. 113 114 Emerging literature suggests that inflammation and glucose metabolites such as methylglyoxal are key factors in the development of pain. 115 116 Attention should also focus on improving our understanding of the differences between type 1 and type 2 diabetes, 59 
STAT E O F T H E A RT R E V I E W RESEARCH QUESTIONS
Which diagnostic test(s) should be used to confirm neuropathy in the clinic and in research studies? What is the optimal treatment algorithm for painful diabetic neuropathy? What are the pathophysiologic differences between type 1 and type 2 diabetes? What is the role of metabolic syndrome components in nerve injury? What is the natural course of neuropathic pain in painful diabetic neuropathy?
